• Kura Oncology highlighted early Phase 1 FIT-001 data for farnesyl transferase inhibitor darlifarnib (KO-2806) combined with cabozantinib in cabozantinib-exposed clear cell renal cell carcinoma.
• Response-evaluable cabo-exposed ccRCC cohort showed objective response rate 44% (7/16) with disease control rate 94% (15/16).
• Responses were reported across dose levels, including ORR 67% (2/3) in darlifarnib 3 mg with cabozantinib 60 mg cohort.
• Safety update in all RCC patients showed grade ≥3 darlifarnib treatment-related adverse events ranging 18% to 67% across cohorts, with neutropenia main severe event.
• Program rationale centered on darlifarnib blocking mTORC1 signaling via RHEB farnesylation, positioning combination to improve activity in VEGFR TKI-treated kidney cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.